Transfusion-associated adverse events incidence and severity after the implementation of an active hemovigilance program with 24 h follow-up. A prospective cohort study.
Bueno JL, Bocanegra AB, Sánchez I, Mateos JM, Puyuelo A, García Erce JA, Villanueva H, Reaño MM, Núñez L, Losa A, Arias A, Aguilar M, Richart LA, Martínez F, Salgado R, Royuela A, Cruz-Bermúdez JL, Fernández R, Forés R, Fornet I, Ojeda E, Cabrera R, Duarte RF.
Bueno JL, et al. Among authors: reano mm.
Transfusion. 2023 Oct;63(10):1859-1871. doi: 10.1111/trf.17538. Epub 2023 Sep 15.
Transfusion. 2023.
PMID: 37711059